EU/3/20/2395: Orphan designation for the treatment of amyotrophic lateral sclerosis

Celecoxib / Ciprofloxacin


On 6 January 2021 orphan designation EU/3/20/2395 was granted by the European Commission to Morrison & Foerster, Belgium, for celecoxib, ciprofloxacin (also known as PrimeC) for the treatment of amyotrophic lateral sclerosis.

Key facts

Active substance
  • Celecoxib
  • Ciprofloxacin
Intended use
Treatment of amyotrophic lateral sclerosis
Orphan designation status
EU designation number
Date of designation

NeuroSense EU GmbH
Seelengraben 24
Mitte 8
9073 Ulm B

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

September 2023The sponsorship was transferred from Ferenc Tracik, Germany to NeuroSense EU GmbH, Germany.
June 2022The sponsorship was transferred from Morrison & Foerster, Belgium to Ferenc Tracik, Germany.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating